Q-omics provides the consensus-scored ZFYVE16 profile across patient tissues and cancer cell-line models. ZFYVE16 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZFYVE16 is differentially expressed in 13, with the highest sampling consensus in LUSC. Additionally, ZFYVE16 RNA expression shows 20,963 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, LUSC, and KIRP as cancer lineages where ZFYVE16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFYVE16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFYVE16 survival associations across molecular data types. ZFYVE16 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFYVE16 RNA expression–survival associations across cancer types. High ZFYVE16 expression shows unfavorable associations in LIHC, KICH and SKCM, but favorable associations in KIRC, HNSC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZFYVE16 RNA expression.
This table summarizes ZFYVE16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZFYVE16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFYVE16 shows lower tumor expression in LUSC, THCA, KICH and KIRP and higher tumor expression in LIHC and CHOL. The LUSC box plot shows higher ZFYVE16 RNA expression in normal versus tumor tissue (log2 FC = −0.550, t-test p < 0.001).
This table shows molecular features associated with ZFYVE16 in patient tissues and cancer cell lines. In patient samples, ZFYVE16 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZFYVE16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
